E214 | The Hard Science of Saving Your Hairline: Modern Medicine vs. Natural Selection
Summary
Androgenetic alopecia accounts for more than 90% of clinical hair loss, driven jointly by genetic susceptibility, androgen pathways, and follicle location. 李昆 puts prevalence at about 21.3% for men and 6.6% for women; follicles on the crown express more androgen receptors and 5α-reductase than those at the sides and occiput, making them more prone to miniaturization. 张晓雨 notes that the condition involves more than 60 genetic loci, many on the X chromosome, and has not been eliminated by natural selection because it usually becomes apparent only at 20–30: “in the course of human evolution, people at that age had already reproduced.”
Finasteride and minoxidil have dominated first-line treatment for decades not because they are interchangeable, but because they target the androgen pathway and improve the follicular environment respectively. Finasteride reduces DHT, while minoxidil opens potassium channels and improves local blood flow; 李昆 likens them to “improving the soil” and “loosening the soil, watering and fertilizing it.” In men, the combination typically produces visible change after about 3 months and better recovery after 6 months. The trade-off is long-term maintenance: “your underlying androgen status has not changed,” so the follicles remain under attack after treatment stops.
The current innovation focus for legacy drugs is to turn twice-daily dosing, systemic exposure, or high-solvent formulations into more tolerable local delivery. The marketed topical finasteride Caretopic delivered efficacy comparable to oral treatment in Phase 3 while reducing blood exposure by at least 50%, but its formulation contains 55% ethanol—equivalent to applying “55-proof liquor to your head every day.” N1 Life is using peptides to deliver finasteride in a purely aqueous formulation; animal and early-model data have been positive, but 张晓雨 explicitly places the program at the “preclinical” stage.
New-mechanism drugs could emerge over the next 3–5 years, but the more likely outcome is a three-way combination rather than a new product displacing minoxidil and finasteride outright. 李昆 cites a $120M-funded MPC inhibitor in Phase 3, an improved latanoprost product that has completed Phase 2, a topical androgen-pathway drug in Phase 3, and a domestic THR agonist that “should have already completed Phase 2.” Since 2022, the FDA has also approved 3 oral JAK inhibitors for severe alopecia areata. His view is that follicular stem-cell activation, the androgen pathway, and potassium-channel activation will “coexist for the long term.”
The hair-loss drug market remains defined by cheap legacy drugs, a large patient base, and the possibility that new drugs could reset the pricing structure. 李昆 estimates the global drug market at “several billion dollars in the high single digits,” including about $2B in Europe and the US. Repriced as novel therapies, pure drug sales could reach $20B–$30B, while adding hair transplants, prevention products, and haircare could bring the total to $40B–$50B. China’s pure drug market is about RMB3B, versus roughly RMB20B for the full market, growing about 15% annually—but these are guest estimates under a new-drug pricing scenario, not established market sizes.
Channel data show that customer acquisition scale and treatment value do not overlap: e-commerce accounts for 70% of sales, hospitals just 10%, yet hospitals bring the most adherent patients with the longest treatment cycles. 李昆 observes that 4G, 5G, and short video have increased the “monetization potential of appearance.” Reviewing global minoxidil API supply, he found increases in both 2016 and 2017, then noted that use also rose in Europe, the US, and Southeast Asia as short video spread. Hair clinics are expanding from Beijing and Shanghai into top-tier provincial hospitals. For brands, “hospitals are the biggest engine”: e-commerce drives volume, while doctors provide diagnosis, trust, and long-term management.
Hair transplants, anti-hair-loss shampoos, and frequent perming or coloring cannot bypass follicular biology; the line between adjunctive and therapeutic products must remain clear. A transplant simply moves relatively androgen-insensitive follicles from the occiput into the thinning area; donor supply is limited, and minoxidil or finasteride is usually still needed afterward. Shampoo is a rinse-off product that stays on the scalp for no more than about 3 minutes, mainly improving sebum, inflammation, and scalp conditions; “there is still a long way from preventing hair loss to growing hair.” Traction from ponytails, plucking gray hairs, and breakage or inflammation from chemical treatments require stopping the ongoing damage first.
振东制药’s experience shows that competition in hair loss is shifting from generic-drug sales toward product, delivery, data, and patient-management capabilities. 达霏欣’s online business roughly doubled each year during its first 5 years after moving online, but 李昆 identifies the real barriers as choosing the right segment, recruiting talent and finding benchmarks, and accepting that innovation requires “constant investment and constant waste.” AI is already being used for target and peptide design, sales BI, e-commerce customer service, overseas market intelligence, and content production. 张晓雨 has built virtual models of the skin and blood-brain barriers using proprietary experimental data, but both guests stress that AI outputs must still be validated against cellular, animal, or human data.
Deep dive
1. More than 90% of hair loss is androgenetic, but classification comes first
张晓雨 puts the clinical share of androgenetic alopecia at more than 90%. The classic male pattern is an M-shaped retreat at the temples, while women more often see a widening part; Mediterranean-style thinning across the crown also mostly falls into this category.
张晓雨 separates out other common types: alopecia areata often appears suddenly as round or oval bald patches and is commonly linked to autoimmunity or psychological stress; scarring alopecia destroys follicles through inflammation, surgery, or genetic disease and is usually irreversible; postpartum changes, high fever, major surgery, or hormone medication can push follicles into the resting phase in large numbers.
李昆 cautions that rapid regional shedding, heavy dandruff, folliculitis, or scalp inflammation may not be androgen-related. Trichoscopy is the better way to determine “whether it is caused by immunity, inflammation, or something else,” rather than self-medicating based only on the amount of hair lost.
Traction alopecia comes from wearing tight ponytails or buns for long periods, or from plucking hair. 张晓雨’s answer to whether pulling out gray hairs damages follicles is blunt: “Yes, absolutely”—the better approach is to cut the hair at the root, because “gray hair is still hair.”
2. The innate sensitivity of crown follicles explains why androgens trigger opposite effects in different areas
The prevalence of androgenetic alopecia is about 21.3% among men and 6.6% among women. 李昆 adds that nearly half of men under 30 in the Middle East, and more than two-thirds of men under 50, are affected. China’s rate is lower than Europe and the US, but the condition is becoming younger and more widespread.
张晓雨 explains that the same androgen can promote beard and body-hair growth while suppressing crown hair. Different follicles establish distinct gene-expression patterns during embryonic development; crown follicles have the highest expression of androgen receptors and 5α-reductase, making them most sensitive to signals such as DHT, while occipital and lateral follicles are relatively insensitive.
Male pattern baldness is not a single-gene disease but involves more than 60 genetic loci, a substantial share of them on the X chromosome. Men have only one X chromosome, so susceptibility variants are more likely to be expressed; women may carry these hair-loss genes without expressing them and pass the risk to their children, creating the appearance of “skipping a generation.”
On why the trait has persisted, 张晓雨’s evolutionary explanation is that androgens support muscle, bone, sexual-organ, and sperm development during puberty, with those advantages appearing before hair loss. Most men do not develop obvious hair loss until 20–30, when natural selection is weaker. She retains one uncertainty: “we still do not really understand” why the crown is particularly sensitive.
3. From observations of eunuchs in ancient Greece to a 1942 experiment, androgens were identified as the cause
More than 400 years before Christ, Hippocrates recorded that “eunuchs never go bald.” Aristotle also observed that men castrated before puberty not only avoided hair loss but failed to grow beards. Both recognized a link between sexual organs, male characteristics, and baldness, but lacked a way to verify the mechanism.
In 1942, American anatomist James Hamilton systematically studied more than 100 eunuchs and normal men. Those castrated before puberty did not develop male pattern baldness; after receiving testosterone, they began to lose hair, and when testosterone was withdrawn, the hair loss stopped. But “the hair that had already been lost never grew back.” The work also established the Hamilton–Norwood classification still used today.
4. A “natural human experiment” in the Dominican Republic turned DHT into a druggable target
In the 1960s, researchers confirmed that the 5α-reductase reaction was irreversible and identified DHT, or dihydrotestosterone, through prostate research. DHT was understood to drive the progressive miniaturization of follicles until they lost their ability to grow.
In 1974, Cornell researchers discovered a group of people in a village in the Dominican Republic who were born with female-appearing anatomy but developed as males after puberty. They lacked 5α-reductase and could not convert testosterone into the more potent DHT. Despite normal or even elevated testosterone, they showed almost no male pattern baldness, sparse facial hair, and very small prostates.
After Merck basic-research scientist Roy Vagelos heard the report, he saw an opportunity to “mimic this physiological deficiency” by inhibiting 5α-reductase with a drug. The project, code-named MK-906, later became finasteride—first used for benign prostatic hyperplasia and subsequently established as a first-line drug for androgenetic alopecia.
5. Minoxidil pivoted from an antihypertensive side effect to “loosening and fertilizing the soil” for follicles
Like Viagra, minoxidil found its second indication through an unexpected side effect: patients taking it orally for hypertension developed excess body hair. Developers later converted it into a topical formulation to reduce the risks of long-term oral use, and the FDA approved it for hair loss in 1988.
李昆 explains that minoxidil opens potassium channels, dilates dermal microvessels, and increases blood flow; it may also affect follicular stem cells. His clinical analogy treats hair as a crop: “minoxidil is essentially loosening the soil,” making it easier for nutrients to reach the roots and slowing androgen-driven follicular miniaturization.
Existing products typically use a 2% concentration for women and 5% for men, usually twice daily. About 10% of people may respond poorly, while others cannot tolerate minoxidil, propylene glycol, or alcohol, making formulation—not the active ingredient itself—the focus of ongoing improvement.
6. Finasteride addresses the cause, minoxidil supports the follicle, and the combination beats either drug alone
李昆 summarizes the division of labor this way: finasteride reduces DHT from inside the body, “improving the soil,” while minoxidil improves blood flow from outside, “loosening the soil.” Their mechanisms do not conflict, which is why the long-standing first-line regimen for men has been topical minoxidil plus finasteride; monotherapy is generally less effective.
Their indications are not identical. Finasteride is highly specific to the androgen pathway and is generally not recommended for women because of reproductive toxicity, although it may be considered after menopause. Minoxidil can also be used for postpartum hair loss, alopecia areata, or traction alopecia, but if the traction habit continues, “using it is basically no different from not using it.” JAK inhibitors currently work better for alopecia areata.
Topical minoxidil–finasteride combinations are available through many UK pharmacies and US compounding pharmacies. Although such sales are not compliant with UK regulations, they reflect substantial clinical demand and awareness. The problem is that both drugs must cross the stratum corneum, and existing combinations often rely on high concentrations and alcohol-based solvents.
7. The next competition for legacy drugs is moving from twice-daily dosing to weekly or even monthly dosing
李昆 says the first core R&D task for mature molecules is formulation improvement: reducing the allergy, greasiness, and irritation caused by propylene glycol and alcohol, while solving the adherence problem that “most people cannot stick with twice a day.”
振东 wants to develop minoxidil or finasteride into once-weekly, once-monthly, or even once-every-2–3-month treatments. 泓君 compares the shift with obesity drugs moving from high-frequency dosing to long-acting formulations: efficacy holds while the burden on patients falls sharply.
Combination products have also opened an intellectual-property window. 李昆 says minoxidil plus finasteride has been studied publicly for a long time, making a combination patent difficult. Researchers, however, found a special concentration–efficacy curve for finasteride on the scalp: efficacy first declines and then rises as concentration increases, leading to approval of a related patent.
8. Topical finasteride lowers systemic exposure but shifts the challenge to skin delivery
张晓雨 emphasizes that oral finasteride travels through the bloodstream to tissues including the prostate and reproductive system. She cites cases of sexual and psychological effects collected by the Post-Finasteride Syndrome organization, including extreme cases. These accounts warrant careful risk management, but the program did not equate individual cases with incidence rates.
The European product Caretopic directly compared topical and oral finasteride in Phase 3, achieving comparable efficacy while reducing blood exposure by at least 50%. When 泓君 asked whether topical treatment eliminated systemic side effects, 张晓雨 gave the more precise answer: risk depends on the amount that ultimately reaches the bloodstream, not simply on whether the label says oral or topical.
Caretopic uses 55% ethanol to aid dissolution and penetration. 张晓雨 describes it as “55-proof liquor applied to your head every day.” High alcohol concentrations can cause irritation and sensitization, and may also allow the drug to keep crossing the skin into circulation. The ideal delivery system would carry the drug through the stratum corneum and leave it in the follicle or dermis.
N1 Life uses peptides instead of organic solvents to achieve follicular drug concentrations close to those of alcohol-based formulations in a purely aqueous system. 张晓雨 says animal and early-model data have been positive, but the product has not entered formal registration trials and remains preclinical; the company is discussing a collaboration with Stanford Skin Innovation Clinic.
9. Side effects, initial shedding, and long-term maintenance determine real-world efficacy
Minoxidil’s most common problems are oily hair, worsening seborrheic dermatitis after vasodilation, and allergic or inflammatory reactions to the active ingredient, propylene glycol, or alcohol. Finasteride may affect male sexual function; although incidence is low, patient acceptance is limited. For women, reproductive risk is a clear constraint.
李昆 also mentions one observation: some people who are quick-tempered find it “hard to get angry” after taking finasteride, possibly because the androgen pathway is being suppressed. He does not define this as an official indication or an inevitable side effect, saying only that “the phenomenon does exist.”
Minoxidil can initially trigger more shedding. As the vascular and follicular environment changes, existing fine hairs may be pushed out by new growth. 张晓雨 believes that an early response often indicates sensitivity to the drug, and patients should not stop immediately because of short-term shedding.
The combination can produce visible change after about 3 months and potentially good recovery after 6 months. Dosage or frequency can then be reduced, but treatment usually cannot be stopped completely. “Androgens will continue attacking the follicles,” so the earlier treatment begins—while follicles have not yet closed—the better the odds of preserving hair.
10. Hair transplants redistribute follicles but cannot end androgen-driven damage
Cosmetic transplantation can use occipital follicles to reshape the hairline or create a widow’s peak. Hair-loss transplantation moves occipital or lateral follicles that are relatively insensitive to androgens into thinning areas, offering visible results and precise local repair.
When 泓君 asked whether transplanted hair could also fall out, 李昆 answered: “Yes, it can.” The transplanted follicles remain in a hair-loss zone and usually still require minoxidil or finasteride, making transplantation a “treat-the-symptom, not the cause” solution.
Donor follicles are finite. If native hair continues to miniaturize, repeated procedures consume the occipital reserve. Patients must also go through crust shedding, temporary loss, and long-term management; the final result depends on physician skill, follicular quality, and scalp condition, with “extremely, extremely large” individual variation.
11. Cheap legacy drugs suppress market value, while new mechanisms could first reset the pricing structure
李昆 estimates the global hair-loss drug market at “several billion dollars in the high single digits,” including about $2B in Europe and the US. Minoxidil and finasteride are priced like common legacy drugs, so even with a huge patient base, sales remain constrained by mature generic pricing.
If future products are priced as new drugs rather than legacy medicines, he expects the pure drug market could reach $20B–$30B. Adding hair transplants, prevention products, and haircare could bring the total to $40B–$50B. This is a scenario based on new-product launches and a reset in pricing.
China’s pure drug market is about RMB3B, while drugs, transplants, prevention products, and haircare together total roughly RMB20B, growing about 15% annually. 李昆 believes that once new products establish a higher price structure, the market will “immediately see a major surge.”
12. The new-drug pipeline is expanding, but 3 mechanisms are more likely to coexist than replace one another
李昆 lists a clinical pipeline that includes an MPC inhibitor funded with $120M and in Phase 3, an improved latanoprost product that has completed Phase 2, 克拉特隆 topical liquid in Phase 3, and a domestic THR agonist that, to his understanding, “should already have completed Phase 2.”
Systemic delivery is also being revisited: the US has an extended-release oral minoxidil tablet, while Australia has a sublingual tablet. When 泓君 asks whether these are “incremental innovation or disruptive innovation,” 李昆 classifies the MPC inhibitor as a new target and new mechanism, while retaining a key uncertainty: “we do not yet know what kind of results follicular stem-cell activation products can achieve.”
His base case is not winner-take-all but the long-term coexistence of 3 categories over the next 3–5 years: activating follicular stem cells, inhibiting 5α-reductase or blocking androgen receptors, and opening potassium channels. “The better approach may be to use all 3 at the same time.”
13. JAK inhibitors bring alopecia areata into the new-drug era and advance personalized combination care
Since 2022, the FDA has approved 3 oral JAK inhibitors for severe alopecia areata, a major recent development in hair loss. 张晓雨 cautions, however, that they are still oral drugs and carry the same trade-offs associated with systemic exposure.
At Stanford’s dermatology innovation clinic, she followed a patient with features of both male pattern baldness and alopecia areata. Advanced trichoscopy quantified follicle count, hair count, and hair thickness while continuously tracking inflammation, redness, and discharge, allowing each follow-up to produce a trend chart rather than relying solely on visual judgment.
The patient initially used a relatively high dose of topical minoxidil, with limited efficacy and worsening inflammation. The doctors then switched to low-concentration minoxidil and added a JAK inhibitor recently approved for atopic dermatitis of the hands, an off-label use.
泓君 interpreted the approach as a Phase 1 clinical trial. 张晓雨 corrected him: the drugs themselves are already approved, so this is not a Phase 1, 2, or 3 registration trial but personalized care based on physician judgment. The clinic later organizes and publishes the follow-up data for other clinicians to learn from.
14. Expansion of hair-care medicine is happening alongside the monetization of appearance through short video
李昆 recalls that before 2016–2017, dermatology in China focused more on vitiligo and psoriasis and ranked relatively low among medical students choosing specialties. In recent years, autoimmune drugs have often used dermatological diseases as their first indication because endpoints are visible and clinical costs are relatively low. Greater income from education and compliant commercial activities has also made dermatology more attractive.
Hair clinics were once concentrated in major hospitals in Beijing and Shanghai; they have now entered some top-tier hospitals in provincial capitals. Public hospitals are also establishing standalone medical-aesthetics departments, using transparent pricing, fewer sales tactics, and clearer accountability to squeeze smaller noncompliant aesthetic clinics.
李昆 initially attributed rising demand for hair-loss care to higher incomes in China. After reviewing global minoxidil API supply, he found increases in both 2016 and 2017, then noted that use also rose in Europe, the US, and Southeast Asia as short video expanded. He ultimately points to 4G, 5G, and short video as the deeper variables: “because people need to be on camera,” appearance has shifted from a personal preference to a monetizable asset.
达霏欣’s channel mix is about 70% e-commerce, 20% pharmacies, and 10% hospitals. Yet hospital patients have the longest treatment cycles and best adherence, so 李昆 still calls hospitals “the biggest engine,” while e-commerce consumers are more likely to try the product and drop out midway.
15. Anti-hair-loss shampoo can improve the scalp environment, but “preventing hair loss” is far from “growing hair”
李昆 draws a clear boundary: neither ordinary nor specially registered anti-hair-loss shampoo can treat androgenetic alopecia on its own, because shampoo mainly acts on the scalp surface and hair shaft and cannot reach the androgen pathway that causes follicular miniaturization.
What products can do is support medication: use milder surfactants to reduce barrier damage, use Sophora flavescens bipeptides to improve the inflammatory environment, use niacinamide and similar ingredients to support scalp condition, and control sebum, the microbiome, and inflammation to facilitate absorption of topical drugs.
Ordinary shampoo can claim volumizing or moisturizing effects. Products claiming to prevent hair loss need basic human testing and may therefore have some ability to reduce shedding, but “there is still a long way from preventing hair loss to growing hair.” People who are already losing hair still need drug treatment.
张晓雨 adds a formulation perspective: shampoo is a rinse-off product that typically remains in contact with the scalp for no more than 3 minutes. Getting ingredients through the stratum corneum and into the follicle in that window is an “extremely demanding challenge.” Without solid clinical data, hair-growth claims should not be treated as evidence of efficacy.
16. Perming, coloring, traction, and inflammation can compound thinning but are not synonymous with androgenetic alopecia
The heat and chemical processing involved in perming and coloring damage the structure of the hair shaft, making it fragile and prone to breakage. Persistent traction from improper styling can also cause premature shedding. Scalp inflammation or barrier damage caused by certain ingredients may trigger telogen effluvium.
泓君 says he used to wear his hair in a ponytail frequently and saw obvious small vellus hairs after applying minoxidil to the front hairline. 张晓雨 cautions that once the hair grows longer, those strands should not be pulled tightly into the ponytail again.
For people with underlying androgenetic alopecia, perming, coloring, or inflammation can amplify thinning. The sequence of treatment still begins with identifying the cause, rather than attributing every broken hair, oily scalp, or flake to DHT.
17. 振东 moved from a hospital-based legacy brand to e-commerce, but the real challenge was becoming product-led rather than sales-led
In 2016–2017, 李昆, the second generation of the family business, was looking for a new growth engine. The team selected 达霏欣, a product with more than 10 years of operating history and a hospital base but weak online sales. After the shift to e-commerce, online business roughly doubled each year for its first 5 years before entering a steadier growth phase.
His first principle is that “choosing well matters more than working hard.” A traditional pharmaceutical company is not a scientist-founded startup, so the segment must fit its resources and direct-to-consumer capabilities. Drug development and sales cycles are both long; one wrong choice can waste 5 years and directly undermine the successor’s managerial authority.
The second step was finding talent and benchmark companies, transforming the organization from selling generics to building products that address efficacy, side effects, and adherence. The third was sustained investment. 李昆’s exact formulation is: “innovation means constant investment and constant waste, and eventually results emerge.” Pulling funding just before the result arrives means writing off the earlier investment as well.
The lesson from the 2019 pet nutrition and sports nutrition projects was that the team had followed marketing trends without understanding the target segments deeply enough. Products are now planned 2–3 years ahead. Even for shampoo or health foods, the company tries to support claims with animal and human data rather than chasing “whatever is popular today.”
18. AI is entering the drug-and-commercial loop, but experimental validation and human oversight remain essential
李昆 says AI is now broadly involved in target and compound design at 振东. Even the traditional Chinese medicine formulas developed with Zhejiang University incorporate calculations covering plant ingredients, targets, and effect strength. AI can propose peptide designs first, after which cell or animal experiments provide feedback, typically through 2–3 iterations. When 泓君 asks whether this produces “scrap molecules,” his answer is that experiments remain part of the process.
Non-drug products are harder to automate end to end. Shampoo combines multiple ingredients and multiple weak pathways, potentially making it more complex than a single-target drug; experimental results are also harder to feed back into a model continuously with the same clarity as drug data. AI therefore remains mainly a tool for screening combinations rather than autonomous product development.
On the commercial side, AI is already used for sales BI, e-commerce customer service, script and video generation, overseas market research, and influencer selection. An AI livestream once attracted viewers for 24 hours, but platform throttling and declining novelty led 振东 back to “AI plus humans.” Medical customer service is still monitored by people to ensure accurate answers on side effects and disease-related questions.
张晓雨 has used experimental data generated by N1 Life to build virtual models of the skin and blood-brain barriers, with the goal of accelerating carrier-molecule design and eventually opening the models to partners. Her advice for ordinary people is more basic: sleep, exercise, control diet and inflammation. 李昆 adds going to bed early, reducing stress, and protecting the scalp from the sun: “when UV is strong, wear a hat.”